Risvodetinib succinate is under clinical development by Inhibikase Therapeutics and currently in Phase I for Dysphagia. According to GlobalData, Phase I drugs for Dysphagia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Risvodetinib succinate LoA Report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Lyell Immunopharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Risvodetinib succinate overview

Risvodetinib succinate (Ikt-148009) is under development for the treatment of Parkinson’s disease (PD), dysphagia, neurogenic constipation and multiple system atrophy. The drug candidate is administered orally. It acts by targeting Abelson tyrosine kinase (BCR-ABL) enzyme and ABL1 (c-Abl). It is developed based on Re-engineering Approach with Metabolism Preserved (RAMP) technology.

Inhibikase Therapeutics overview

Inhibikase Therapeutics is a biotechnology business dedicated to the development and commercialization of small-molecule kinase inhibitor therapeutics for the safe and effective treatment of neurological illnesses both inside and outside the brain. The company is headquartered in Atlanta, Georgia, the US.

For a complete picture of Risvodetinib succinate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.